NCT06074744 Subsartorial Nerve Block and Femoral Nerve Block in Total Knee Arthroplasty
| NCT ID | NCT06074744 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Luzerner Kantonsspital |
| Condition | Joint Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 144 participants |
| Start Date | 2023-11-30 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 144 participants in total. It began in 2023-11-30 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare two different types of nerve blocks in patients undergoing surgery for primary Total Knee Arthroplasty. The main question aim to answer is: \- is there a benefit in functional muscle power output of the leg? Participants will be randomized into either the intervention group or the control group and: * receive Subsartorial Saphenous Nerve Block (SSNB) + IPACK in intervention group (group 1) * receive Femoral Nerve Block (FNB) + IPACK in control group (group 2) Researchers will compare the 2 groups to see if there are differences in : * functional muscle power output of the leg? * muscle function, mobility, clinical and radiological results, ROM, pain control (NRS), opioid consumption, length of hospital stay, patient satisfaction, mobility, reduction of costs?
Eligibility Criteria
Inclusion criteria: * age \> 18yrs * primary TKA * BMI 35kg/m2 or less * able to give informed consent as documented by signature * clinical history without any contraindications for the planned intervention Exclusion criteria: * age \< 18 years * revision-TKA * BMI \>35kg/m2 * absent contact information * inability or contraindications to undergo the investigated intervention (TKA, FNB, SSNB), - clinically significant concomitant diseases * pregnancy * inability to follow the procedures and follow-up procedures of the study (e.g. due to language problems, psychological disorders, dementia, living abroad, etc. * withdrawal from the study
Contact & Investigator
Judith Bering, Dr. med.
PRINCIPAL INVESTIGATOR
Luzerner Kantonsspital Luzern
Frequently Asked Questions
Who can join the NCT06074744 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Joint Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06074744 currently recruiting?
Yes, NCT06074744 is actively recruiting participants. Contact the research team at judith.bering@luks.ch for enrollment information.
Where is the NCT06074744 trial being conducted?
This trial is being conducted at Lucerne, Switzerland.
Who is sponsoring the NCT06074744 clinical trial?
NCT06074744 is sponsored by Luzerner Kantonsspital. The principal investigator is Judith Bering, Dr. med. at Luzerner Kantonsspital Luzern. The trial plans to enroll 144 participants.